UnknownPHASE2, PHASE3NCT05322187

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy

Studying Hepatoblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
RenJi Hospital
Principal Investigator
Hao Feng, M.D
Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU
Intervention
PD-1 inhibitor(drug)
Enrollment
15 target
Eligibility
5-14 years · All sexes
Timeline
20222023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05322187 on ClinicalTrials.gov

Other trials for Hepatoblastoma

Additional recruiting or active studies for the same condition.

See all trials for Hepatoblastoma

← Back to all trials